Abbvie ((ABBV)), Genmab (Otc) ((GMAB)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The recent clinical study update from AbbVie and Genmab focuses on a Phase 1/2 trial titled ‘A Phase 1/2, Open-label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma.’ The study aims to evaluate the safety, dosage, and efficacy of epcoritamab in treating B-cell lymphoma, a significant step in addressing relapsed or refractory cases.
Epcoritamab, the intervention being tested, is a biological treatment administered via subcutaneous injections. It is designed to target and treat B-cell lymphoma by engaging the immune system to attack cancer cells.
The study employs an interventional design with a sequential intervention model and no masking, focusing primarily on treatment. Participants are allocated to receive active treatment without a placebo group, ensuring direct assessment of the drug’s effects.
The trial began on June 26, 2018, with its primary completion and estimated completion dates yet to be updated. The last update was submitted on August 4, 2025, indicating ongoing progress in the study.
This update could positively impact AbbVie and Genmab’s stock performance by enhancing investor confidence in their oncology pipeline. As the study progresses, it may also influence the competitive landscape in the B-cell lymphoma treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.